Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cerevel Therapeutics Hldg Inc (CERE)

Cerevel Therapeutics Hldg Inc (CERE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,920,761
  • Shares Outstanding, K 148,289
  • Annual Sales, $ 0 K
  • Annual Income, $ -225,330 K
  • 60-Month Beta 2.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.67
Trade CERE with:

Options Overview Details

View History
  • Implied Volatility 134.67% ( +18.18%)
  • Historical Volatility 79.18%
  • IV Percentile 99%
  • IV Rank 95.38%
  • IV High 138.05% on 07/01/21
  • IV Low 64.83% on 12/22/21
  • Put/Call Vol Ratio 8.76
  • Today's Volume 2,498
  • Volume Avg (30-Day) 322
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 7,767
  • Open Int (30-Day) 8,016

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.50
  • Number of Estimates 5
  • High Estimate -0.47
  • Low Estimate -0.55
  • Prior Year -0.42
  • Growth Rate Est. (year over year) -19.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.10 +19.64%
on 06/16/22
29.81 -11.30%
on 06/27/22
-0.81 (-2.97%)
since 05/27/22
3-Month
19.86 +33.13%
on 05/12/22
38.37 -31.09%
on 04/04/22
-7.18 (-21.36%)
since 03/30/22
52-Week
19.59 +34.93%
on 07/15/21
46.16 -42.72%
on 11/08/21
+0.82 (+3.20%)
since 06/30/21

Most Recent Stories

More News
Cerevel Therapeutics Announces Updates to its Board of Directors

CAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain...

CERE : 27.26 (+3.10%)
Cerevel Therapeutics to Present at the Jefferies Healthcare Conference

CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain...

CERE : 27.26 (+3.10%)
Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Data for the darigabat Phase 2...

CERE : 27.26 (+3.10%)
Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022

CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain...

CERE : 27.26 (+3.10%)
Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022

Oral presentation to highlight preclinical data demonstrating robust antiepileptic activity for darigabat in drug-resistant focal epilepsy Poster...

CERE : 27.26 (+3.10%)
Cerevel Therapeutics to Present at the Stifel 4th Annual CNS Day Event

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain...

CERE : 27.26 (+3.10%)
Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2021 Financial Results

Announced positive results from Phase 1 healthy volunteer trial of darigabat in acute anxiety On track to initiate two parallel adequately-powered Phase 2...

CERE : 27.26 (+3.10%)
Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain...

CERE : 27.26 (+3.10%)
Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety

In healthy volunteers, both the 7.5 mg and 25 mg twice-daily doses of darigabat demonstrated a clinically meaningful and statistically significant...

CERE : 27.26 (+3.10%)
Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program for Emraclidine (CVL-231) in Schizophrenia to be Presented

Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia ...

CERE : 27.26 (+3.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cerevel Therapeutics Inc. treats neuroscience diseases. The company's diversified pipeline comprising clinical-stage investigational therapies and several preclinical compounds to treat neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics...

See More

Key Turning Points

3rd Resistance Point 28.67
2nd Resistance Point 28.04
1st Resistance Point 27.24
Last Price 27.26
1st Support Level 25.81
2nd Support Level 25.18
3rd Support Level 24.38

See More

52-Week High 46.16
Fibonacci 61.8% 36.01
Fibonacci 50% 32.88
Fibonacci 38.2% 29.74
Last Price 27.26
52-Week Low 19.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar